A reassessment of risks and benefits of dopamine agonists in Parkinson's disease

Angelo Antonini, Eduardo Tolosa, Yoshikuni Mizuno, Mitsutoshi Yamamoto, Werner H. Poewe

Research output: Contribution to journalArticlepeer-review


Neurologists have several choices of drugs that have been shown to be effective for the treatment of the symptoms of Parkinson's disease. Among the first options are the dopamine agonists, which are commonly used both as an early monotherapy and as an adjunct therapy to levodopa. However, before starting any treatment, the overall benefit-to-risk ratio to individual patients must be considered. For the dopamine agonists, the available evidence on their symptomatic efficacy, effect on long-term levodopa-related motor complications, putative effect on progression of disease, and adverse event profile must be taken into account. Recently, the ocurrence of adverse events such as leg oedema, daytime somnolence, impulse control disorders, and fibrosis have increasingly been recognised. The risks of these potentially serious adverse events must therefore be taken into account and treatment decisions should be based on considerations of risks versus benefits for individual patients.

Original languageEnglish
Pages (from-to)929-937
Number of pages9
JournalThe Lancet Neurology
Issue number10
Publication statusPublished - Oct 2009

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'A reassessment of risks and benefits of dopamine agonists in Parkinson's disease'. Together they form a unique fingerprint.

Cite this